Search Our Website:

Barbara Binzak Blumenfeld, shareholder in the firm's Life Sciences Industry Group, was featured in Bloomberg Law article, “Stem Cell Clinics Face Mounting Attack From Federal Enforcers.”

The latest lawsuit suggests “a possible uptick in both FTC and state enforcement actions against entities that are marketing unapproved stem cell therapies,” Barbara Binzak Blumenfeld, an FDA attorney with Buchanan Ingersoll & Rooney, said.

Many people may think that the FDA has sole federal authority over the regulation of stem cell products, Binzak Blumenfield added. But while the FDA has a specific regulatory scheme for such products, the FTC Act prohibits unfair or deceptive acts or practices, as well as false advertising for drugs either in or affecting commerce.